Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear.
T urner syndrome (TS) is a disorder in females that is
caused by the complete or partial absence of the second sex chromosome. It is one of the most common chromosomal disorders, affecting approximately one in 2000 live-born girls (1) . Untreated adult patients are on average 20 cm shorter than healthy women (2) , mainly due to haploinsufficiency of the short stature homeobox-containing gene (3) . GH therapy increases adult height with 5-12 cm (4 -6) , and the addition of the weak androgen oxandrolone (Ox) may further increase adult height (7) (8) (9) . However, in previous studies Ox dosages of 0.1 mg/kg ⅐ d or greater had to be lowered to 0.05 and 0.06 mg/kg ⅐ d (7-9) on the frequent findings of virilizing side effects and increased bone maturation. Although the recommended Ox dosage is currently 0.05 mg/kg ⅐ d or less (10) , the efficacy and safety of such dosage is unclear. We hypothesized that, due to the effect of Ox on bone maturation, the optimal dosage with respect to final height gain could be lower than 0.06 mg/kg ⅐ d and therefore performed a doseresponse study. In this randomized, placebo-controlled, double-blind study, we assessed the benefit to risk ratio of Ox at a low (0.03 mg/kg ⅐ d) and previously conventional dosage (0.06 mg/kg ⅐ d) in GH-treated girls with TS.
Participants and Methods

Participants
Participants were recruited in 10 pediatric endocrine centers in The Netherlands from December 1991 to June 2003. Inclusion criteria were a karyotype associated with TS (except for cytogenetical evidence of Y chromosomal material); a calendar age between 2.00 and 15.99 yr; and a bone age younger than 12.00 yr (11) . Exclusion criteria were growth failure due to other causes; use of drugs that could interfere with growth; and previous GH, sex hormone, or androgen therapy. The study was performed in accordance with the World Medical Association Declaration of Helsinki and approved by the ethics committee of each participating center. Before enrollment, written informed consent was obtained for each patient.
Treatment
Patients were included in age group 1 (2.00 -7.99 yr), 2 (8.00 -11.99 yr), or 3 (12.00 -15.99 yr). After stratification for calendar age and height SD score (SDS) (12) , they were randomized by a computer-generated schedule with a block size of six and blindly assigned to receive, orally at bedtime after reaching the age of 8 yr, Ox 0.03 mg/kg ⅐ d (Ox 0.03) (S.p.A., Milano, Italy), Ox 0.06 mg/kg ⅐ d (Ox 0.06), or a similar appearing placebo (Pl). The capsules were manufactured and distributed by one hospital pharmacy. All patients and doctors were blinded for the allocation of the patients and will remain so until the last patient will finish the study. Only the independent pharmacist (Dr. C. M. A. Rademaker), the statistician (M.A.J.d.R.), and data analyst (L.A.M., from 2008 onward) saw unblinded data, but none of them had any contact with the participants. From baseline onward, biosynthetic human GH (1.33 mg/m 2 body surface per day, at 1 m 2 equivalent to 46 g/kg ⅐ d) was administered sc at bedtime. Genotropin (Pfizer Inc., New York, NY) was used in age groups 1 and 2 and Humatrope (Eli Lilly, Indianapolis, IN) in age group 3. Ox/Pl was started at the age of 8 yr after a number of years of GH therapy (i.e. at their main year visit) in age group 1 and at inclusion in age groups 2 and 3 (i.e. between the age of 8.0 and 16.0 yr). In the absence of spontaneous puberty [Tanner breast stage Ͻ2 (B2) (13)], estrogen therapy was started between the age of 12.0 and 12.99 (after a number of full years of GH therapy) in age groups 1 and 2 and at inclusion (i.e. between the age of 12 and 16 yr) in age group 3. 17-ß-Estradiol was prescribed in age groups 1 and 2 and ethinyl-estradiol in age group 3 (5 and 0.05 g/kg ⅐ d orally, increased to 10 and 0.1 g/ kg ⅐ d after 2 yr, respectively). When ethinyl- 
FIG. 1.
Enrollment, randomization, and analysis of the patients. IGT, Impaired glucose tolerance. Some patients were excluded from the per-protocol analysis for more than one reason; the sum of these numbers may therefore not equal the total number of patients in these boxes.
estradiol became unavailable after March 2002, 17-ß-estradiol was also prescribed in age group 3. Cyclic progesterone was added after at least 2 yr of estrogen therapy. Doses were adjusted every 6 months, and GHϩOx/Pl were stopped when height velocity was less than 1 cm per 6 months or when patients decided to stop because they were satisfied with their height. Thereafter patients were followed up for two subsequent year visits to measure growth after discontinuing GHϩOx/Pl.
Assessments
Two trained observers performed all half-yearly measurements during the total study period. The primary outcome was adult height gain (centimeters), defined as adult height (the last measured height after discontinuing GHϩOx/Pl) minus predicted adult height, calculated using the modified projected adult height method (mPAH) (14) . Briefly, Lyon et al. (15) used longitudinal heights of untreated TS girls to modify the projected adult height (which assumes that adult height SDS is equal to height SDS at a younger age) into a regression equation predicting adult height in TS. Adapted to North European TS girls (2), this equation is: mPAH ϭ 146.95 ϩ 6.37 ϫ (Ϫ0.2 ϩ 0.836 ϫ height SDS at baseline) (14, 16) . Height was measured at every visit using a Harpenden stadiometer. The mean of four measurements was expressed as SDS for healthy Dutch girls (17) and untreated Northern European girls with TS (2) using Growth Analyser (www.growthanalyser.org). To avoid overestimation of adult height SDS in patients who stopped growing at an earlier age than healthy peers or untreated girls with TS, reference data for the age of 21 yr instead of the actual age were used for calculating adult height SDS. Target height (centimeters) corrected for sex and secular trend was defined as: 0.5 ϫ (height maternal ϩ height paternal Ϫ 13) ϩ 4.5 (17) .
Secondary outcomes included the influence of age group on the effect of Ox, and the effect of Ox on: short-term height gain, adult height gain adjusted for bone age at start, safety parameters, pubertal development, bone maturation, and duration and costs of GH therapy. To assess bone maturation (⌬bone age/ ⌬calendar age), one trained, and up until 2008, blinded investigator (L.A.M.) determined bone ages of the yearly made hand x-rays retrospectively and chronologically according to the Tanner and Whitehouse radius, ulna, short-bones score (11) . Pubertal stages were assessed half yearly according to Tanner (13) and expressed as SDS adjusting for age and sex (18) . The cumulative amount of GH prescribed was multiplied by 44.32 euro/mg (Genotropin, www.fk.cvz.nl, 2009) to obtain cumulative costs of GH therapy.
All adverse events reported by the patient, parent, or medical doctor were registered. Virilizing adverse events included voice deepening, clitoral enlargement, or an increase in body hair, all being previously identified as Ox-related virilization (7) (8) (9) 19) . These events were included in the analysis if a girl reported virilization at least twice (i.e. either the same complaint at two visits or two complaints at one visit) or if the girl decided to discontinue Ox/Pl because of the event. Dynamap blood pressure (BP) monitoring was performed half yearly. The latter three of four measurements were averaged and expressed as SDS adjusting for age, gender, and height (20) . Blood samples were taken at starting GH, after 6 months, yearly, and 6 months after discontinuing GHϩOx/Pl. Determinations included plasma IGF-I, IGF binding protein (IGFBP)-3, glycosylated hemoglobin (HbA1c), aspartate c Ox/Pl therapy was started between the age of 8.0 and 8.99 yr, after a number of years of GH therapy in age group 1 and at inclusion (i.e. between the age of 8 and 16 yr) in age groups 2 and 3. Because (according to the protocol) GH and Ox were not started at the same time in age group 1, the age at starting GH is not equal to the age at starting Ox;
d Estrogen therapy was started between the age of 12.0 and 12.99 (after a number of years on GH therapy) in age groups 1 and 2 and at inclusion (i.e. between the age of 12 and 16 yr) in age group 3;
e if puberty was induced, the moment at starting estrogens was used; if puberty developed spontaneously, the moment at Tanner breast stage 2 was used;
f for the analysis of the safety parameters, the eight patients who did not start Ox/Pl were excluded. . IGF-I and IGF-I to IGFBP-3 molar ratio were transformed into SDS using reference levels for healthy Dutch children (21) . HbA1c levels were measured using a dedicated automatic HPLC analyzer (DIAMAT from 1991 to 1997 and VARIANT from 1997 to 2008; Bio-Rad Laboratories, Inc., Edgemont, CA). Both methods produced identical results (upper normal assay limit Ͻ6.6%).
Statistical analyses
We estimated that 15 patients per dosage and age group were needed to achieve a power of 80% to detect a difference (P ϭ 0.05, two sided) in first-year height velocity of 2 cm with an assumed SD of 2.6. Intention-to-treat analyses were performed and differences in adult height gain were also assessed by a perprotocol analysis. Safety parameters were assessed in a modified intention-to-treat analysis, in which patients who refused to start Ox/Pl therapy were excluded. When Ox/Pl was discontinued before discontinuing GH, the moment at which GH was discontinued was identified as at discontinuing GHϩOx/Pl. Differences between dosage groups were tested by linear regression using two dummies (for GHϩOx 0.03 and GHϩOx 0.06) and differences in proportions by Pearson 2 tests and Fisher's exact tests. Means were compared with zero by a one-sample t test. Differences in change of outcome variables during the study period were assessed by repeated-measurements analysis. Models were fitted with a different intercept and slope per dosage group and a random intercept and slope per patient. To assess the influence of the age groups, interaction terms between age groups and dosage groups were used. Figure 1 shows the 133 patients that were randomized. Four patients were lost to follow-up and nine patients were still treated when the analysis started in May 2008. Of the 120 patients included in the intention-to-treat analysis, the parents of eight girls refused Ox/Pl because of fear of side effects and/or satisfaction with growth. After excluding all protocol-violators, 82 patients (68%) were left for the per-protocol analysis.
Results
Patient characteristics
Adult height gain
Baseline data were similar between the dosage groups ( Table 1 ). Figure 2 shows the height SDS before, during, and after discontinuing GHϩOx/Pl therapy. The 2-yr increase in height SDS was significantly greater on GHϩOx 0.03 and 0.06 than on GHϩPl (P Ͻ 0.001 for both comparisons), but differences decreased before reaching adult height. Figure 3 shows the individual heights of the 120 girls at starting GH therapy as well as after reaching adult height. Adult height gain, measured 1.9 Ϯ 0.8 yr after discontinuing GH, was greater than zero in each dosage group (P Ͻ 0.001 for all comparisons) (Fig. 4) . Compared with GHϩPl, it was 2.3 cm greater on GHϩOx 0.03 [95% confidence interval (CI) 0.4 -4.2, P ϭ 0.02] and 1.2 cm greater on GHϩOx 0.06 (95% CI Ϫ0.8 to 3.2, P ϭ 0.3) (Fig. 4A) . Similar results were obtained when leaving out the eight patients who did not start Ox/Pl therapy (data not shown) and when analyzing the increase in height SDS from baseline to adulthood (Table 2 ). When correcting for bone age at starting GH therapy, the difference in adult height gain compared with GHϩPl was 1.8 cm on GHϩOx 0.03 (P ϭ 0.05) and 1.0 cm on GHϩOx 0.06 (P ϭ 0.3). In the per-protocol analysis, adult height gain was 3.1 cm greater on GHϩOx 0.03 (95% CI 0.5-5.6, P ϭ 0.02) and 2.2 cm greater on GHϩOx 0.06 (95% CI Ϫ0.6 to 4.9, P ϭ 0.1) (Fig. 4B) . Note that Ox/Pl therapy was started between the age of 8.0 and 8.99, after a number of years of GH therapy in age group 1 and at inclusion (i.e. between the age of 8 and 16 yr) in age groups 2 and 3. Height SDS at starting GH therefore reflects untreated values, whereas height SDS at starting Ox/Pl includes values from girls who had already been treated with GH. Height SDS at the last visit was calculated using reference values for 21-yr-old girls. The asterisk indicates that mean first 2-yr increase in height SDS was greater than on GHϩPl (P Ͻ 0.001).
Bone maturation was greater in both GHϩOx groups than on GHϩPl (GHϩOx 0.03, P ϭ 0.007; GHϩ0.06, P Ͻ 0.001) ( Table 2 ). When corrected for bone age at starting GH, the duration of GH therapy was shorter on GHϩOx 0.03 and 0.06 (Ϫ0.4 yr and Ϫ0.8 yr, P ϭ 0.06 and P ϭ 0.001, respectively), and the cumulative costs of GH were lower (Ϫ10,100 Ϯ 6,100 and Ϫ13,500 Ϯ 6,300 euro, P ϭ 0.1 and P ϭ 0.03, respectively) than on GHϩPl (mean cumulative costs,161,200 Ϯ 59,500 euro).
Supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org, shows the baseline and clinical data per-age group and per-dosage group. In the intention-to-treat analysis, mean adult height gain in age groups 1, 2, and 3 was 9.4 Ϯ 4.4, 6.0 Ϯ 3.6, and 5.8 Ϯ 2.6 cm on GHϩPl; 10.4 Ϯ 5.8, 9.0 Ϯ 4.4, and 8.6 Ϯ 3.0 cm on GHϩOx 0.03; and 10.0 Ϯ 3.7, 9.0 Ϯ 4.8, and 5.4 Ϯ 4.7 cm on GHϩOx 0.06, respectively. Among the three age groups, no statistically significant difference in the effect of Ox on adult height gain was found.
Pubertal development
Puberty started spontaneously in 28 girls (mean age at B2, 11.1 Ϯ 1.0 yr). In the remaining 92 girls, estrogen therapy was started at a mean age of 12.8 Ϯ 0.9 yr. In the years thereafter, breast stage SDS of the girls that had started Ox/Pl (modified intention to treat analysis, n ϭ 112) increased less on GHϩOx 0.03 and 0.06 than on GHϩPl (during first 2 yr, P ϭ 0.05 and 0.1, respectively; until discontinuing GHϩOx/Pl, P ϭ 0.02 and 0.05, respectively) ( Table 2 ). Breast stage SDS at discontinuing Ox/Pl was lower on GHϩOx 0.03 than on GHϩPl (P ϭ 0.01) and although it caught up after discontinuing Ox and increasing estrogen dosages, it was still lower on GHϩOx 0.03 than on GHϩPl after discontinuing GHϩOx/Pl (P ϭ 0.04) ( Table 2 ). Pubic hair stage SDS increased significantly more on GHϩOx 0.03 and 0.06 than on GHϩPl during the first 2 yr of Ox/Pl (P ϭ 0.008 and 0.003, respectively), but the increase during the total duration of Ox/Pl therapy was not significantly different between the dosage groups ( Table 2) . Mean pubic hair stage SDS at discontinuing Ox/Pl was, however, significantly greater on GHϩOx 0.06 than on GHϩPl (P ϭ 0.003).
Adverse events and virilization
During the study, 2030 adverse events were reported, none of which were considered GH related. Twenty-three girls reported a total of 40 virilizing adverse events (Table  2) , and more girls on GHϩOx 0.06 than on GHϩPl reported virilization (P Ͻ 0.001). One girl on GHϩOx 0.03 and seven on GHϩOx 0.06 (vs. zero on GHϩPl, P ϭ 0.005) discontinued Ox because of virilization. After discontinuing Ox/Pl, two girls (from groups GHϩOx 0.03 and 0.06) still reported hirsutism, and one girl (from group GHϩOx 0.06) still reported having a low voice. However, hirsutism relieved in three girls, subjective voice deepening relieved in two girls (all from group GHϩOx 0.06), and clitoral size appeared less in two girls (from group GHϩOx 0.03). The other complaints of virilization were not reported anymore.
BP
Mean systolic and diastolic BP (Tables 1 and 2 ) was significantly higher than in healthy girls, at both starting and discontinuing GHϩOx/Pl (P Ͻ 0.001 for all comparisons). During Ox/Pl, systolic BP SDS tended to decrease somewhat more on GHϩOx 0.06 than on GHϩPl (P ϭ 0.06), whereas changes in diastolic BP SDS were not significantly different between the dosage groups ( Table 2) .
Biochemical evaluation
Compared with GHϩPl, mean IGF-I SDS just before discontinuing GHϩOx tended to be greater on GHϩOx 0.03 an 0.06 (corrected for values at starting Ox/Pl, P ϭ 0.09 and 0.05, respectively), and the proportion of patients with an IGF-I greater than 2 SDS at least once during therapy was greater (GHϩOx 0.03, P ϭ 0.04; GHϩOx 0.06, P ϭ 0.06) ( Table 2 ). The change of IGF-I SDS as well as IGF-I to IGFBP-3 ratio during the first year of Ox/Pl therapy was, however, not significantly different between the dosage groups ( Table 2) .
After starting Ox/Pl, five girls had intermittently elevated ASAT and/or ALAT levels (Table 2) , and five girls (three on GHϩOx 0.03 and two on GHϩOx 0.06) developed hypothyroidism and started thyroxine supplementation.
One girl, who already had an impaired glucose tolerance at baseline, had impaired glucose tolerance and an elevated HbA1c (7.7%) after 2 yr of GHϩOx 0.03 therapy. She therefore discontinued GHϩOx, after which HbA1c and glucose levels returned to normal. The HbA1c levels of all other girls remained normal, and none of the girls developed diabetes mellitus type 1 or 2.
Discussion
In the past 2 decades, several trials suggested that the addition of Ox to GH positively affected adult height in girls with TS (7) (8) (9) . However, these studies enrolled smaller numbers of patients, were neither randomized nor placebo controlled, and had to lower their Ox starting dosages (Ն0.1 mg/kg ⅐ d) on the frequent finding of virilizing adverse events. Our randomized, placebo-controlled, double-blind study shows that GH combined with Ox at a previously not studied low dosage (0.03 mg/kg ⅐ d) moderately increases adult height gain and has an acceptable safety profile except for a small deceleration in breast development. The addition of the previously conventional Ox dosage (0.06 mg/kg ⅐ d) does not significantly increase adult height gain and causes virilization in a large proportion of patients.
During the first 2 yr after starting Ox/Pl, the increase in height SDS on GHϩOx 0.03 and 0.06 was significantly greater than on GHϩPl. Adult height gain on GHϩOx 0.06 was, however, smaller than on GHϩOx 0.03, which may be explained by the relatively frequent premature discontinuation of Ox 0.06 because of virilization and the increase in bone maturation with increasing Ox dosages. In contrast, the growth-promoting effect of GHϩOx 0.03 outweighed the increase in bone maturation, resulting in an increased adult height gain compared with GHϩPl.
The exact mechanism by which Ox increases bone growth and maturation is uncertain. A recent report showed that bone growth in vitro was not influenced by Ox, suggesting that Ox may mainly influence the growth plate in an indirect way (22) . Ox does not appear to increase GH secretion (23) , but it may increase growth by increasing IGF-I (presumably by increasing insulin induced hepatic GH receptors) (24) , suppressing IGFBP-I (an inhibitor of IGF-I) (24) , and/or increasing free estrogen levels due to an Ox-induced decrease in SHBG (24, 25) .
FIG. 4. Adult height gain in the intention-to-treat analysis (A) and perprotocol analysis (B)
. Diamonds represent adult height gain (adult height minus predicted adult height) of the individual patients; lines represent mean adult height gain per dosage group. Mean adult height gain was greater than zero in each dosage group (P Ͻ 0.001 for all comparisons in both analyses). Compared with GHϩPl, adult height gain was greater on GHϩOx 0.03 (P ϭ 0.02 both in the intention to treat analysis and per protocol analysis) and not significantly greater on GHϩOx 0.06.
Testosterone is thought to increase bone maturation primarily via the aromatase-induced local conversion to estradiol (25, 26) . The increase in bone maturation due to the nonaromatizable androgen Ox, however, shows that androgens may also influence bone maturation either directly or indirectly via other pathways (27) .
We found that the addition of Ox to GH therapy delayed breast development to some extent. Although breast stage SDS caught up after discontinuing GHϩOx and increasing estrogen dosages, it was still lower on GHϩOx 0.03 than on GHϩPl. Particularly nonaromatizable androgens (such as Ox and dihydrotestosterone) are known to inhibit the stimulatory effect of estrogens on the mammary gland (28) . This inhibitory effect may possibly be overcome by increasing estrogen dosages, although a further acceleration of bone maturation would then perhaps eliminate the positive effect of Ox on adult height.
Several girls on GHϩOx 0.06 reported virilization, and about half of them decided to discontinue Ox for that reason. The finding that also some girls on GHϩPl complained of virilization reflects that part of the reported virilization may be regarded physiological and/or that patients tended to report virilization because they knew this could be a consequence of Ox. Whereas hirsutism and clitoromegaly seem to regress after discontinuing Ox (9, 19) , voice deepening appears irreversible (29) .
Several other adverse events were scarce. As expected in adolescents with TS, a few patients developed hypothyroidism (30) . Although Ox at higher dosages may elevate liver enzymes in non-TS patients (31), we did not find such an effect at the dosages we studied. We further found that the addition of Ox did not increase diastolic BP, whereas systolic BP even tended to decrease on GHϩOx 0.06 vs. GHϩPl. One patient discontinued GHϩOx 0.03 because of an increased HbA1c and an impaired glucose tolerance, after which HbA1c and glucose levels returned to normal. Patients with TS are at an increased risk of developing insulin resistance, and GH therapy, especially when combined with Ox 0.06 mg/kg ⅐ d or greater, may increase this risk (24, 32, 33) . This effect, however, appeared to be reversible after discontinuation of therapy (34) . IGF-I levels were more frequently increased on GHϩOx than on GHϩPl, whereas the increase in IGF-I levels and IGF-I to IGFBP-3 ratio (an indicator of free IGF-I) was not significantly different between the dosage groups. Previous studies also showed conflicting results regarding the effect of Ox on IGF-I levels and IGF-I to IGFBP-3 ratio (35, 36) .
The addition of Ox is not the only strategy to increase adult height gain in TS. Adult height gain may also be augmented by increasing GH dosages, rather than adding Ox to GH therapy (6) . Increasing GH doses would, however, increase IGF-I levels (6) as well as costs, whereas our data show that Ox may lower the GH-associated costs. A further argument in favor of adding Ox is that it may result in a more physiological hormonal status, considering the androgen-insufficient state of untreated girls and women with TS (37, 38) . Another strategy to increase adult height gain is to start GH therapy at a relatively young age. Our finding that mean adult height gain on GHϩPl was 9.4, 6.0, and 5.8 cm in age groups 1, 2, and 3, respectively, confirms that an early diagnosis and start of GH therapy positively influences adult height gain (6) .
Our study has some limitations. First, although it included a follow-up period of 1.9 Ϯ 0.8 yr after discontinuation of GHϩOx/Pl, a longer follow-up would be needed to assess long-term safety. Second, we did not study quality of life and well-being. We hypothesize that the observed delay in breast development may negatively affect these parameters, whereas the increase in height during therapy as well as the decrease in duration of GH therapy (i.e. sc injections) may have some positive effects. Compensating the androgenic insufficiency in TS may also have some positive effects, similar to the effect on well-being observed in androgen-treated adult patients with TS (39) . Finally, no standardized scoring system was used in the assessment of the virilizing adverse events. Consequently, the reported virilization may underestimate the actual occurrence of virilization. Because we were unable to compare the girls with healthy girls in puberty, it is additionally unclear whether the reported virilization should be regarded as genuine virilization or a normalization from an androgen-insufficient state. The relatively great number of patients that discontinued Ox 0.06 due to virilization, however, suggests that this dosage indeed results in virilization.
We conclude that in GH-treated girls with TS, Ox in a conventional dose (0.06 mg/kg ⅐ d) has limited efficacy and gives rise to virilizing side effects. We therefore discourage its use. The addition of low-dose Ox (0.03 mg/ kg ⅐ d) modestly increases adult height gain and has a fairly good safety profile, except for a small deceleration in breast development. In patients considering this deceleration less important than the increment in height gain, Ox 0.03 mg/kg ⅐ d may be added to GH to increase height. d defined as adult height minus predicted adult height; e in the analysis of the safety parameters, the eight patients who had not started Ox/Pl were excluded; f if puberty was induced, the moment at starting estrogens was used; if puberty developed spontaneously, the moment at Tanner B2 was used;
g Ox/Pl therapy was started after a number of years of GH therapy in age group 1 and at baseline in age groups 2 and 3;
h corrected for values just before starting Ox/Pl therapy; i defined as elevated ASAT (Ͼ60 U/liter) and/or ALAT levels (Ͼ50 U/liter) at two or more visits during and/or after discontinuing GHϩOx/Pl therapy.
